Prelude Therapeutics Stock News

Prelude Therapeutics Inc (PRLD) shares closed today at 0.7% above its 52 week low of $8.80, giving the company a market cap of $449M. The stock is currently down 23.5% year-to-date, down 87.2% over the past 12 months, and down 63.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 49.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 514.1% The company's stock price performance over the past 12 months lags the peer average by 178.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Offic

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec.

– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRM

- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors  PRT543 and PRT811 to be Presented in 4Q21 –

Prelude Therapeutics Inc's (NASDAQ:PRLD) share price represents “a particularly attractive buying opportunity,” and the stock has catalysts in the back half of the year, according to BofA Securiti

Prelude Therapeutics (PRLD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, toda

WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced

WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M -